Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

April 30, 2018

Conditions
Opioid Dependence
Interventions
DRUG

Naltrexone intramuscular suspension

A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered

DRUG

Buprenorphine-naloxone

Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).

Trial Locations (5)

Unknown

Akershus University Hospital, Oslo

Haukeland University Hospital, Bergen

Stavanger University Hospital, Stavanger

Vestfold Hospital Trust, Tønsberg

0407

Oslo University Hospital, Avdeling for Rus og Avhengighet, Oslo

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

collaborator

The Royal Norwegian Ministry of Health

OTHER

collaborator

Norwegian Institute of Public Health

OTHER_GOV

collaborator

Oslo University Hospital

OTHER

collaborator

University Hospital, Akershus

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

The Hospital of Vestfold

OTHER

collaborator

Ostfold Hospital Trust

OTHER

lead

University of Oslo

OTHER

NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway | Biotech Hunter | Biotech Hunter